Glaukos vs Myriad Genetics
Myriad Genetics is the larger business, with $825m of revenue in fiscal 2025 against $507m for Glaukos (1.6 times as much). Glaukos grew faster (32.3% against -1.6%). Glaukos kept more of each dollar of sales as profit: a net margin of -37.0% against -44.4%. Glaukos carries less debt relative to equity (0.0% against 34.0%).
| Latest fiscal year | GlaukosGKOS, 2025 | Myriad GeneticsMYGN, 2025 |
|---|---|---|
| Revenue | $507m | $825m |
| Revenue growth | 32.3% | -1.6% |
| Net income | −$188m | −$366m |
| Operating margin | -39.3% | -47.0% |
| Net margin | -37.0% | -44.4% |
| Return on equity | -26.4% | -68.5% |
| Free cash flow | −$22.5m | $1.8m |
| Cash | $90.8m | $150m |
| Total debt | $0 | $125m |
| Debt to equity | 0.0% | 34.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 1,094 | 2,700 |
| Market value | $14.03bn | $567m |
| Price vs our value range | — | — |
| Moat score | 28 (Weak) | 26 (Weak) |
| Insider trades, 12 months | 0 buys, 61 sales | 5 buys, 1 sales |